Influence of Periodontal Treatment on Systemic Inflammatory Mediators

NCT ID: NCT01201746

Last Updated: 2016-10-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

317 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently the research issue in establishing the role of periodontal disease (PD) in coronary heart disease (CHD) risk is to define the pathways that lead to cause-effect relationship between PD and CHD. There is no consensus on definition of a periodontal disease case or the threshold level that may give clear indication for this relationship. Periodontal therapy has been used in different studies with the hope that a change in periodontal disease status may modify the factors associated with CHD risk. Many of these studies, on role of periodontal therapy in the reduction of CHD associated risk-factors, were based on small study samples, and very few studies were randomized controlled trials. So a need for large prospective studies is warranted in literature.----------- A single-blind parallel-arm randomized controlled clinical trial was designed to observe the influence of periodontal treatment on serum inflammatory mediators of hsC-reactive protein, white blood cells and fibrinogen in CHD patients.

Hypothesis: Periodontal therapy in CHD patients, by reducing periodontal inflammation, may decrease the host systemic inflammatory burden associated with atherogenic processes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Disease Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Periodontal Therapy

Scaling Root planing and oral hygiene instructions

Group Type EXPERIMENTAL

Periodontal therapy

Intervention Type PROCEDURE

Scaling, root planning and oral hygiene instructions

Delayed treatment

Scaling Root planing and oral hygiene instructions

Group Type PLACEBO_COMPARATOR

Delayed treatment

Intervention Type PROCEDURE

Scaling, Root Planing and oral hygiene instruction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Delayed treatment

Scaling, Root Planing and oral hygiene instruction

Intervention Type PROCEDURE

Periodontal therapy

Scaling, root planning and oral hygiene instructions

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Control group Experimental group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A. General/Medical

1. Any race/ethnic group
2. Aged \> 30 years
3. Male or female
4. CHD case (CHD angiographically confirmed)
5. CHD diagnosed \> 3 months prior to entry into study.

Exclusion Criteria

8. Non-smoker (=Never smoker) or former smoker (=Does not smoke now and has not smoked at all for a minimum of the last 12 consecutive months)
9. Able and willing to comply with study procedures
10. Able and willing to be available for the duration of the study
11. Able and willing to provide signed informed consent

B. Oral/Periodontal

1. Dentate with at least 14 natural teeth, excluding third molars, that can be evaluated periodontally.
2. Baseline whole mouth BOP \> 20% of sites.
3. Periodontitis case; periodontitis case defined as subject having ≥ 4 teeth with ≥ 1 site with PPD ≥ 4 mm \& CAL ≥ 3 mm at same site
4. No mechanical periodontal therapy in the last 6 months.
5. No acute oral diseases (mucosal lesions), oral infections, need for immediate dental/periodontal care (e.g., NUG).


A. General/Medical

1. Age ≤ 30 years
2. Not fulfilling criteria of defined CHD case
3. Fulfilling criteria of defined CHD case, but diagnosed ≤ 3 months prior to start of study
4. Current smoker
5. Former smoker who does not smoke but who has smoked ≥ 1 cigarette (or equivalent, in form of water pipe, pipe, cigar) in the last 12 months.
6. Females pregnant or lactating
7. Systemic chronic conditions known to be associated with periodontitis or with changes in systemic inflammation: Diabetes,Rheumatoid Arthritis, Rheumatic Fever, SLE, Malignancy, Respiratory diseases, Renal diseases, Other (e.g., autoimmune diseases, fungal infections, immunological deficiencies, etc.)
8. Systemic acute conditions known to affect systemic markers of inflammation: Acute bacterial infection, Acute viral infection (common cold, influenza, sinusitis), Orthopedic trauma, Surgery
9. Medications known to affect systemic inflammatory biomarkers: Statins, Systemic steroids, Non-steroidal anti-inflammatory drugs, Immunosuppressants,
10. Medications potentially affecting systemic inflammatory markers, if therapy started less than 3 months prior to study such as Hormone replacement therapy, Contraceptives
11. Systemic antibiotic therapy in the last 3 months
12. Unable or unwilling to comply with study procedures
13. Unable or unwilling to be available for the duration of the study
14. Unable or unwilling to provide signed informed consent

B. Oral/Periodontal

1. \<14 teeth that can be periodontally evaluated (excluding 3rd molars)
2. BOP ≤ 20% of sites
3. Not fulfilling criteria of defined periodontitis case
4. Having received any periodontal therapy within last 6 months
5. Topical/local antibiotic or anti-inflammatory therapy in last 6 months
6. Acute oral infections
7. Oral wounds, including recent (\< 2 months) extractions
Minimum Eligible Age

31 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Higher Education Commission (Pakistan)

OTHER

Sponsor Role collaborator

Sheikh Zayed Federal Postgraduate Medical Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Syed Akhtar Hussain Bokhari

PhD Candidate

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ayyaz A Khan, Ph.D.

Role: STUDY_DIRECTOR

Sheikh Zayed Federal Postgraduate Medical Institute

Syed Akhtar H Bokhari, MCPS

Role: PRINCIPAL_INVESTIGATOR

Sheikh Zayed Federal Postgraduate Medical Institute

Mohammad Azhar, MRCP

Role: STUDY_CHAIR

Punjab Institute of Cardiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Punjab Institute of Cardiology

Lahore, Punjab Province, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HEC-20-685/06

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

PU-D/314/Acad

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Periodontitis Treatment and Heart Failure
NCT07036289 ENROLLING_BY_INVITATION NA